<DOC>
	<DOCNO>NCT00524680</DOCNO>
	<brief_summary>RATIONALE : Vitamin D may effective treat patient prostate cancer . PURPOSE : This randomized phase II trial study well 4 different dos vitamin D work treat patient prostate cancer .</brief_summary>
	<brief_title>Vitamin D Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To examine pattern response serum 25 ( OH ) D3 level follow cholecalciferol ( vitamin D3 ) supplementation four different oral dos patient prostate cancer . Secondary - To examine pattern response parathormone ( PTH ) follow vitamin D3 supplementation patient . - To assess toxicity vitamin D3 supplementation men prostate cancer . Tertiary - To track occurrence infection , deep vein thrombosis , vascular event , fall patient . OUTLINE : Patients randomize 1 4 treatment arm . - Arm I : Patients receive 4,000 IU oral cholecalciferol ( vitamin D3 ) daily . - Arm II : Patients receive 6,000 IU vitamin D3 daily . - Arm III : Patients receive 8,000 IU vitamin D3 daily . - Arm IV : Patients receive 10,000 IU vitamin D3 daily . Treatment arm continue 6 month absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate 25 ( OH ) D3 level &lt; 80 ng/mL PATIENT CHARACTERISTICS : Inclusion criterion : ECOG performance status 02 Creatinine ≤ 2.0 mg/dL Corrected serum calcium ≤ 10.5 mg/dL Exclusion criterion : History malabsorption syndrome ( e.g. , pancreatic insufficiency , celiac disease , tropical sprue ) Hypersensitivity cholecalciferol one component PRIOR CONCURRENT THERAPY : No concurrent vitamin D supplementation</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>